Hydrogen sulfide prodrugs—a review  by Zheng, Yueqin et al.
Institute of Materia Medica, Chinese Academy of Medical Sciences
H O S T E D  B Y Chinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2015;5(5):367–377http://dx.doi.org/10.10
2211-3835 & 2015 Ch
Elsevier B.V. This is
nCorresponding auth
E-mail address: w
Peer review under rwww.sciencedirect.comREVIEWHydrogen sulﬁde prodrugs—a reviewYueqin Zheng, Xingyue Ji, Kaili Ji, Binghe WangnDepartment of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta,
GA 30303, USA
Received 5 May 2015; accepted 3 June 2015KEY WORDS
Hydrogen sulﬁde (H2S);
Gasotransmitters;
H2S prodrugs;
H2S-hybrid nonsteroidal
anti-inﬂammatory drugs;
Controllable H2S
prodrugs;
Hydrolysis-based H2S
prodrugs16/j.apsb.2015.06.00
inese Pharmaceutica
an open access artic
or. Tel.: þ1 404 41
ang@gsu.edu (Bing
esponsibility of InstAbstract Hydrogen sulﬁde (H2S) is recognized as one of three gasotransmitters together with nitric
oxide (NO) and carbon monoxide (CO). As a signaling molecule, H2S plays an important role in
physiology and shows great potential in pharmaceutical applications. Along this line, there is a need for
the development of H2S prodrugs for various reasons. In this review, we summarize different H2S
prodrugs, their chemical properties, and some of their potential therapeutic applications.
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Hydrogen sulﬁde (H2S), a well-known lethal, toxic gas with the
smell of rotten eggs, is recognized as one of the three gasotrans-
mitters in mammals, which also include nitric oxide (NO) and
carbon monoxide (CO)1–6. The literature evidence suggests that
hydrogen sulﬁde possesses the following activities: anti-
inﬂammatory7–9, anti-tumor10, ion channel regulation11–13, cardio-
vascular protection14–16 and antioxidation17. However, the exact
role that hydrogen sulﬁde plays depends on the speciﬁc circum-
stance, its concentration, and the interplays with other signaling
molecules, especially NO and CO18. This is a major area of
research in developing hydrogen sulﬁde-based therapeutics, but is
beyond the scope of this review. Another major issue is ﬁnding
appropriate ways of delivering hydrogen sulﬁde to the relevant
location, at the right concentration, and with the appropriate
pharmacokinetics. Much of this issue stems from the fact that it
is unrealistic to use gaseous hydrogen sulﬁde itself or its salt such
as sodium sulﬁde in therapeutic applications in human. Thus there
is a great deal of interest in searching for appropriate hydrogen-
sulﬁde-releasing agents, which are commonly referred to as H2S
donors or prodrugs. This review provides a summary of develop-
ments in this ﬁeld mostly during the last ﬁve years with a focus on
the chemistry concepts19.
1.1. H2S chemistry
H2S is a weak acid and soluble in water (up to 80 mmol/L at
37 1C20). The pKa values (37 1C) for the ﬁrst and second
dissociation steps are about 6.88 and 19, respectively21. Under
physiological conditions (pH¼7.4), H2S largely exists in two
forms: the neutral molecular form (H2S) and an ionic form (HS
)
(Scheme 1). S2 is a very minor component simply because of the
second pKa being very high. However, the bioactive form is still
unknown, and the term H2S is usually used referring to the total
sulﬁde species. Although H2S has good solubility in water, it is
still very unstable in solution. It is easy oxidized in the presence of
oxygen. In addition, the volatility of hydrogen sulﬁde adds
complications to experiments. For example, half of the dose of
H2S could be lost in 5 min from open cell culture wells
22. H2S
concentration can decrease so rapidly that the precise measurement
of H2S concentration is a great challenge in this ﬁeld
23–28.
1.2. H2S biology
In mammals, three enzymes are involved in sulfur-containing
amino acid metabolism and thus responsible for the in vivo
production of H2S. Two of them are pyridoxal-50-phosphate
(PLP)-dependent enzymes: cystathionine β-synthase (CBS) and
cystathionine γ-lyase (CSE). CBS is expressed predominantly in
the central nervous system (CNS)29. Relatively high concentra-
tions (47 μmol/L to 166 μmol/L) of H2S have been observed in the
brains of mammals30–32. The normal cellular function of CBS is in
the trans-sulfuration pathway, catalyzing the condensation of
homocysteine with serine to form cystathionine. In the 1980s,Scheme 1 Hydrogen sulﬁde disassociation19, where pKa1¼6.88,
and pKa2¼19.CBS isolated from rat liver and kidney was reported to produce
H2S from cysteine
33. In contrast to CBS, CSE is mainly
responsible for the production of H2S outside of the CNS
7. CBS
and CSE share a common feature of catalytic promiscuity. The
relative contributions of CBS and CSE to H2S generation at low
homocysteine concentration are about 7:3. However, CBS activity
is conﬁned to chemical transformations at the β-position34, while
CSE is proﬁcient at catalyzing reactions at the β- and γ-carbons of
substrates35. Furthermore, because homocysteine appears to be
unable to bind to the site at which the external aldimine with PLP
is formed in CBS, CSE's contribution to the H2S pool is increased
under conditions of moderate and severe hyperhomocysteinemia.
A third H2S-producing enzyme, 3-mercaptopyruvate sulfurtrans-
ferase (3MST), was thought to exist, as H2S was not depleted in
CBS knockout mouse brain36. 3MST, a PLP-independent enzyme,
is localized in the neurons in the brain along with cysteine
aminotransferase (CAT), while CBS is localized in the astrocytes,
a type of glia, in the CNS. 3MST and CAT are also found in the
vascular endothelium. CAT catalyzes the reaction of L-cysteine
with α-ketoglutarate to form 3-mercaptopyruvate (3MP), which is
further catalyzed by 3MST to generate H2S in the presence of thiol
and reducing agents (Fig. 1)37. Overall, H2S production in
mammals is intimately connected to the metabolic pathways of
sulfur containing amino acids. The PLP-dependent trans-sulfura-
tion pathway, which contains both CBS and CSE for H2S
production, is localized in the cytosol. H2S synthesis via CAT
and 3MST occurs in the cytosol and mitochondria.2. H2S prodrugs
In the past several years, many series H2S prodrugs have been
developed. They could be divided into three general classes: plant-
derived natural products, hydrolysis-based H2S prodrugs, and
controlled-release H2S prodrugs.
2.1. Plant-derived natural products
Allium vegetables, represented by garlic and onions, have long
been considered as salubrious foods that have anti-inﬂammatory
functions, and their active ingredients have been shown to reduce
the risk of diabetes and cardiovascular diseases38–40. It was not
until 2007 that studies from Kraus' group showed that theFigure 1 Enzymatic pathways of H2S production in mammalian
cells.
Hydrogen sulﬁde prodrugs 369vasoactivity of garlic compounds was correlated with H2S
production41, which suggested that the major beneﬁcial effects
of allium vegetable diets are mediated by the biological production
of H2S from organic polysulﬁdes.
To date, several sulfur-containing components from garlic or
garlic preparations have been identiﬁed (γ-glutamylcysteines and
alliin in the intact garlic; ajoene and allyl mercaptan in the steam-
distilled garlic oil; S-allyl-cysteine and S-allyl-mercaptocysteine in
the aged garlic extract; and methiin in the garlic homogenate).
Among all the different components, only three of them, S-allyl-
cystein (SAC), diallyl disulﬁde (DADS), and diallyl trisulﬁde
(DATS) have been shown to have pharma cological effects, which
are correlated with the H2S signaling pathway
41,42. DADS and
DATS are major components of garlic oil43, and are derived from
allicin, which is unstable in water (Scheme 2).
Organic polysulﬁdes DADS and DATS act as H2S donors when
they react with biological thiols including GSH, or by human red
blood cells via glucose-supported reactions. It is proposed that
DADS undergoes nucleophilic substitution at the α-carbon and
yield a key intermediate allyl perthiol to form H2S (Scheme 3).
The chemical conversion of organic polysulﬁdes to H2S is
facilitated by allyl substituents and dependent on the number of
tethering sulfur atoms. Another study of DADS found that the
hepatocyte cytotoxicity of DADS might be attributed to the
inhibition effect of H2S on cytochrome oxidase
44, suggesting
biological production of H2S from DADS.
The third sulfur-containing compound in allium vegetables
related to H2S production is S-allyl-cysteine (SAC), a reduced
form of alliin, which is the major component in aged garlic extract.
Studies from Zhu0s group42,45 showed that SAC and CR-SPRC, a
cysteine analog of SAC, upregulated CSE expression and
increased plasma H2S concentrations. Rats used in an acute
myocardial infarction and heart failure model were treated with
SAC or CR-SPRC, respectively. It was found that SAC and its
analog signiﬁcantly lowered mortality and improved cardiac
function. The activity of CSE, CAT, GSH, and plasma H2S
concentration were increased in SAC-pretreated and CR-SPRC-
treated rats, suggesting its cardioprotection effect via a H2S-
mediated pathway. However, there is no report on H2S production
directly from SAC in the biological systems.
Recently, Kondo et al.46 published a H2S prodrugs: SG-1002
(Fig. 2), which is a polysulfur mixture containing 92% α sulfur,
7% sodium sulfate and a trace amount of other sulfur derivatives.
In one study, SG-1002 was administered to C57BL/6J or CSEScheme 2 Sulfur-containing compounds in intact gar
Scheme 3 Proposed H2S production fknockout mice to investigate the effects of genetic modulation of
CSE and exogenous H2S in a pressure overload-induced heart
failure model. It was found that CSE knockout mice exhibited
signiﬁcantly greater cardiac dilatation and dysfunction than wild-
type mice after transverse aortic constriction, and cardiac-speciﬁc
CSE transgenic mice maintained cardiac structure and function
after transverse aortic constriction. H2S afforded by SG-1002
could upregulate the vascular endothelial growth factor (VEGF)-
Akt-endothelial nitric oxide synthase (eNOS)-nitric oxide (no)-
cGMP pathway with preserved mitochondrial functions, attenuated
oxidative stress, and increased myocardial vascular density. The
results show oral H2S therapy prevents the transition from
compensated to decompensated heart failure in part via upregula-
tion of endothelial nitric oxide synthase and increased nitric oxide
bioavailability. However what needs to be noted concerning these
studies is that the mechanism of H2S release from SG-1002 is not
described. More studies are needed to prove the correlation of H2S
production and the observed pharmacological effects.
2.2. Hydrolysis-based H2S prodrugs
Hydrolysis-based H2S prodrugs primarily consist of four classes of
analogs: namely, inorganic sulﬁte salts including NaHS, Na2S and
CaS; Lawesson's reagent and analogs; 1,2-dithiole-3-thiones
(DTTs); and arylthioamides derivatives. For arylthioamides deri-
vatives, some classiﬁed them as thiol-activated H2S donors. Since
these compounds are easily hydrolyzed to generate H2S in PBS
buffer, they are summarized in this section.
2.2.1. Inorganic sulﬁte salts
NaHS and Na2S are two widely used H2S donors in basic research.
Upon hydrolysis, both compounds could generate H2S quickly in
PBS buffer (pH 7.4). In aqueous state under physiological pH, the
ratio of HS/H2S is around 3:1
19,47.
NaHS and Na2S have been extensively used in studying the
biological effect of hydrogen sulﬁde. For example, in an
ovalbumin-treated rat model48, NaHS treatment could increase
peak expiratory ﬂow (PEF), and decrease goblet cell hyperplasia,
collagen deposition score, the total cells recovered from bronchoal-
veolar ﬂuid, and inﬂux of eosinophils and neutrophils. Addi-
tionally, administration of NaHS also signiﬁcantly attenuated
activation of pulmonary inducible nitric oxide synthase (iNOS).
Those results suggested that H2S possessed anti-inﬂammatory andlic resulting from conversion of amino acid alliin.
rom DADS by reactions involving thiol.
Figure 2 The structure of α sulfur in SG-1002.
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cystathionine-gamma-lyase (CSE)/H2S pathway. Using NaHS as a
H2S donor, Du et al.
8 examined the possible role of H2S in the
pathogenesis of oleic acid (OA)-induced acute lung injury (ALI)
and its regulatory effects on the inﬂammatory response. Intraperi-
toneal injection of NaHS (56 mmol/L) into OA-treated rats
increased the pressure of oxygen in the arterial blood (PaO2),
reduced the lung wet/dry ratio and alleviated the degree of ALI.
Additionally, NaHS decreased inﬂammatory cytokine such as IL
(interleukin)-6 and IL-8 levels and increased anti-inﬂammatory
cytokine IL-10 levels in the plasma and lung tissues. Similarly,
Na2S inhibited IL-1β levels and signiﬁcantly increased anti-
inﬂammatory cytokine IL-10 levels in an acute lung injury
model49.
In addition to anti-inﬂammatory effect, NaHS or Na2S also
showed pro-inﬂammatory50–52, ion channel regulation11,12, cardi-
ovascular53, and neurogenic regulation54 effects. Although NaHS
and Na2S presented promising biological results both in vitro and
in vivo, the likelihood of their use in clinical applications is small
due to reasons such as release kinetics, smell, lack of ability to
target, and difﬁculty in controlling its concentration because of
hydrogen sulﬁde's volatility. Nevertheless, encouragingly, a
sodium sulﬁde solution (IK-1001) for intravenous injection has
successfully completed a phase I clinical trial, thus pointing to the
possibility of applications in well-deﬁned situations4.
Another potential inorganic H2S donor is calcium sulﬁde (CaS),
which is one of the effective components in a traditional medicine,
hepar sulphuris calcareum55. Compared to NaHS and Na2S, CaS is
chemically more stable. However, there is only limited information
on the effectiveness of CaS as H2S donor
56.2.2.2. Lawesson's reagent and analogs
Lawesson's reagent, which is widely used for sulfurization in
organic synthesis57, also releases H2S upon hydrolysis, and it has
been used as a H2S donor in some studies. Compared to inorganic
sulﬁde, the release rate with Lawesson's regent is much slower.
After incubation of Lawesson's reagent in buffer or rat liver
homogenate for 60 min, the conversion to H2S was about 18% or
11%, respectively58. In work by Medeiros et al.59, Lawesson's
reagent was used as H2S donor to evaluate its protective effect
against alendronate (ALD)-induced gastric damage in rats. In this
study, Lawesson0s reagent was orally administrated once daily for 4
days. Induction of gastric damage by ALD (30 mg/kg) was seen
30 min after ALD administration. The results showed that pretreat-
ment with Lawesson's reagent (27 mmol/kg) attenuated ALD-
mediated gastric damage, reduced TNF-α, IL-1β, and malondialde-
hyde formation; lowered myeloperoxidase activity; and increased
the level of GSH in the gastric tissue. All those results suggested
that Lawesson's reagent plays a protective role against ALD-induced
gastric damage by activation of ATP-sensitive potassium (KATP)
channels. In another study60, Lawesson's reagent also attenuated
ethanol-induced macroscopic damage in a dose-dependent fashion.
However, Lawesson's reagent also releases H2S spontaneously uponhydrolysis in aqueous solution, and it suffers from poor water
solubility, which may pose a limit for its further applications.
GYY4137, a water-soluble derivative of Lawesson's reagent,
could also release H2S upon hydrolysis
16. Compared to Law-
esson's reagent and sulﬁde salts, it can generate H2S at a slower
rate. With the use of the H2S microelectrode or the DTNB (5,
5-dithiobis-(2-nitrobenzoic acid)) assay, it was found that incuba-
tion of GYY4137 in aqueous solution (pH 7.4, 37 1C) resulted in
the release H2S, and the concentration of H2S peaked at around
6–10 min, and remained at a low level (o10 mmol/L) over a
sustained period of 100 min. In one experiment, the administration
of GYY4137 (133 mmol/kg i.v. or intraperitoneal) to anesthetized
rats could also boost the concentration of H2S in plasma to around
75 mmol/L at the 30 min point, and the concentration remained
elevated (above 40 mmol/L) for more than 180 min. Additionally,
GYY4137 did not cause any signiﬁcant cytotoxic effect, or alter
the cell cycle proﬁle or p53 expression of cultured rat vascular
smooth muscle cells. However, NaHS was previously reported to
induce apoptotic cell death of cultured ﬁbroblasts and smooth
muscle cells. The differences in the safety proﬁle between
GYY4137 and NaHS may be attributed to the differences in
H2S release rate and the concentration of H2S generated.
In work published by Liu et al.61, GYY4137 was employed as a
H2S donor to investigate its effects on CVB3-induced myocarditis
and possible underlying mechanisms. The results showed that
GYY4137 suppressed CVB3-induced secretion of enzymes impli-
cated in cardiocyte damage including LDH, CK-MB, and
decreased the level of pro-inﬂammatory cytokines, such as TNF-
α, IL-1β and IL-6. Moreover, GYY4137 also inhibited the
activation of NFκB and the IκBα degradation induced by CVB3.
Notably, the phosphorylation of p38, ERK1/2 and JNK1/2 induced
by CVB3 was also suppressed by GYY4137. Taken together,
GYY4137 exerted its anti-inﬂammatory effect in CVB3-infected
cardiomyocytes, which was possibly associated with H2S genera-
tion by GYY4137. The anti-inﬂammatory mechanism may be
associated with the inhibition of NFκB and the mitogen-activated
protein kinase (MAPK) signaling pathway.
Additionally, at a concentration of 400 or 800 mmol/L,
GYY4137 also showed some anti-cancer effect with 30%–70%
death in seven different human cancer cell lines (HeLa, HCT-116,
Hep G2, HL-60, MCF-7, MV4-11 and U2OS)62 and no effect on
the survival of normal human lung ﬁbroblasts (IMR90, WI-38). In
contrast, NaHS did not showed any anticancer effect (400 mmol/L),
and only showed less potent growth inhibition (15%–30%,
800 mmol/L). The author attributed such difference to the different
H2S release rate between GYY4137 and NaHS. Incubation of
GYY4137 (400 mmol/L) in culture medium released low concen-
trations (o20 mmol/L) of H2S, with the concentration sustained
over a period of 7 days. In contrast, incubation of NaHS
(400 mmol/L) in the same way led to much higher concentrations
(up to 400 mmol/L) of H2S with a much shorter duration (1 h). It is
well-known that the effect of H2S is concentration-dependent with
high concentrations (above 250 mmol/L) being toxic63, thus it is
easy to understand that release kinetics and peak concentration
would make much difference to the overall effect of a H2S donor.
The in vivo antitumor effect of GYY4137 was also evaluated. In a
xenograft mice model (HL-60 and MV4-11 cells), GYY4137
could signiﬁcantly inhibit tumor growth at dosages of 100–
300 mg/kg/day.
Despite all the success described above, other independent
studies sometimes showed opposite effect when NaHS was used as
a donor. For example, H2S in the form of NaHS showed protective
Hydrogen sulﬁde prodrugs 371effect for colon cancer cells64, increased proliferation of colon
cancer cells, and reduced apoptosis in several cell lines65. These
disparate observations may be due to the use of different H2S
donors, which release H2S at different rates, give different
byproducts, and have different peak concentrations. Although
ZYJ1122 (Fig. 3), an analog of GYY4137 lacking sulfur, was
inactive in all cancer cell lines tested, it is unclear what byproducts
GYY4137 would generate in cells, because the metabolism for
GYY4137 is expected to be complicated. Additionally, it should
be kept in mind that the percentage of hydrolysis for GYY4137 is
low, which means that the majority of GYY4137 remained in the
cells. Since relatively high concentrations of GYY4137 was used
(400 and 800 mmol/L), it is entirely possible that the observed
anticancer effect may be caused by GYY4137 itself or its
metabolism products, and not necessarily the released H2S. The
convoluted situation with the observed effects of “H2S” is a strong
indication that future experiments need to be benchmarked against
a standard and standard conditions with careful control and
documentation of concentrations.
In order to tune the H2S release capability of GYY4137,
structural modiﬁcations on the phosphorodithioate moiety were
made to GYY4137 to afford a series of O-substituted
phosphorodithioate-based H2S donors (Fig. 3)
66. Their H2S
releasing properties were evaluated by ﬂuorescence methods.
After incubation (100 mmol/L) in PBS buffer (pH 7.4) for 3 h at
room temperature, N,O-diarylated donors and GYY4137 could
release H2S with a ﬁnal concentration of around 800 nmol/L.
However, the O-alkylated donors showed very weak H2S produc-
tion (data not shown in the paper). The protective effects of N,O-
diarylated donors against H2O2-induced oxidative damage in
H9C2 cells were investigated. Speciﬁcally, the donors were
incubated with the cells for 24 h before H2O2 was added. Then
cell viability was determined by the CCK-8 assay after incubation
for another 5 h. The results showed that in the absence of a H2S
donor, cell viability decreased by about 65%. In the presence of
H2S donors (N,O-diarylated donors, GYY4137 and NaHS), a
much higher level cell viability was observed, especially for one
N,O-diarylated donor, which increased the cell viability to about
95% at the concentration of 100 mmol/L. These results suggested
that the H2S donors did present protective effects against oxidative
injury. As mentioned above, the biological results obtained for
these donors should be carefully associated with the generation of
H2S. Further experiments may be needed to clarify this.2.2.3. Arylthioamides derivatives
A series of arylthioamides were synthesized by Vincenzo Calder-
one et al.67, and their H2S release properties were evaluated. The
synthesized compounds were incubated with or without L-cysteine
in PBS buffer at 37 1C, and H2S release was recorded by
amperometry. The results showed that compounds 1–3 (Fig. 4)
did not generate a detectable level of H2S (o2 mmol/L) in the
absence of L-cysteine; however, they did release H2S in theFigure 3 The chemical structures for Lpresence of L-cysteine with Cmax of about 10 mmol/L. For
compounds 4 and 5 with strong electron-withdrawing substituents,
no detectable levels of H2S were observed with or without L-
cysteine. Based on those results, it seems that the H2S release
mechanism for arylthioamides is thiol-activated, and Xian et al.68
did classify arylthioamides as thiol-activated H2S donors. How-
ever, some analogs in this series also generated detectable amounts
of H2S in the absence of L-cysteine, especially compound 12,
which did not show any difference in the amount of H2S released
with or without L-cysteine. It is well characterized that hydrolysis
of thioacetamide would lead to H2S formation. So it could be
concluded that the hydrolysis of arylthioamides could also give
H2S. Actually, Wallace et al.
69 classiﬁed these compounds as
hydrolysis-based H2S donors. It may be more reasonable to say
that both mechanisms contribute to H2S generation because there
is no clear evidence to exclude either.
After conﬁrmation of H2S release from arylthioamides, com-
pound 1 was chosen for further pharmacological studies. It
strongly abolished the noradrenaline-induced vasoconstriction in
isolated rat aortic rings and hyperpolarized the membranes of
human vascular smooth muscle cells in a dose-dependent fashion.
After oral administration of compound 1, the systolic blood
pressure of the animals was signiﬁcantly reduced. These ﬁndings
make arylthioamides promising H2S donors for further study.
No matter what the H2S release mechanism for arylthioamides
is, it should be noted that incubation of 1 mmol/L of the donors
only release H2S with a Cmax value of about 10 mmol/L, which
means that the major species in solution is still the donor itself.
Thus it is still premature to associate the observed bioactivities
with the generation of H2S alone, because the bioactivities may be
caused by the donor itself or a combination of various species.
Actually, this issue is quite common among the organic H2S
donors. More detailed and well-designed control experiments are
needed to address this issue.2.2.4. 1,2-Dithiole-3-thiones and H2S-hybrid nonsteroidal anti-
inﬂammatory drugs
1,2-Dithiole-3-thiones (DTT) has also been used as a H2S donor.
Although its H2S-release mechanism is still not fully clariﬁed, it is
widely accepted that hydrolysis is part of the underlying mecha-
nism for the generation of H2S from DTT
57.
The use of nonsteroidal anti-inﬂammatory drugs (NSAIDs)
suffers from unacceptable risk of gastrointestinal ulceration and
bleeding70–73. In order to reduce such side effects, DTTs have
been conjugated to NSAIDs to form HS-hybrid NSAIDs (HS-
NSAIDs, Fig. 5), which showed signiﬁcant reduction of gastro-
intestinal damage compared to the parent NSAIDs73,74. In addi-
tion, HS-NSAIDs also boosted the anti-inﬂammatory effect of
their NSAIDs counterparts. In a work by Fiorucci et al.75, DTT
was conjugated to diclofenac to afford a HS-NSAID-hybrid
ATB337, and its anti-inﬂammatory effect was investigated along
with diclofenac in rats. In a rat air pouch model, orallyawesson's reagent-based H2S donors.
Yueqin Zheng et al.372administrated ATB-337 dose-dependently suppressed the activity
of both COX-1 and COX-2, and the efﬁciency was comparable to
that of the diclofenac. Additionally, pretreatment with ATB-337
and diclofenac led to a reduction of carrageenan-induced paw
swelling volume. Notably, pretreatment with ATB-337 at 10 mmol/
kg achieved a reduction in edema formation comparable to that
seen with diclofenac at 30 mmol/kg. This enhanced potency was
probably associated with the generation of H2S from ATB-337.
An enhanced anti-inﬂammatory effect was also observed for
ATB-42976. In addition to their anti-inﬂammatory effect, other
HS-NSAIDs including HS-sulindac (HS-SUL), HA-aspirin (HS-
ASA), HS-ibuprofen (HS-IBU), and HS-naproxen (HS-NAP),
were also reported to exhibit anti-proliferative effect against
human colon, breast, pancreatic, prostate, lung, and leukemiaFigure 4 The chemical structures for arylthioamides.
Figure 5 The chemical stru
Figure 6 The chemical struccancer cell lines. The conjugation with 5-(4-hydroxyphenyl)-1,2-
dithiol-3-thione (ADT-OH) signiﬁcantly increased the growth
inhibitory effect of NSAID by 28- to 43000-fold77.
Along the line of NSAID's antiproliferation effect, Kashﬁ
et al.78 prepared a compound NBS-1120 (Fig. 6), which could
release NO, H2S and aspirin at the same time. NBS-1120 inhibited
HT-29 colon cancer growth with IC50 values of 45.572.5,
19.773.3, and 7.772.2 nmol/L at 24, 48, and 72 h time points,
respectively. This is the most potent NSAID-based anticancer
agent so far. Mechanistic studies showed that NBS-1120 induced
apoptosis, and arrested the cells at G0/G1 phase. NBS-1120 also
showed promising in vivo antitumor effect. It signiﬁcantly
inhibited tumor growth by 85% in mice bearing a human colon
cancer xenograft.
Accumulating evidence supports that H2S plays a vital role in
the modulation of mitochondrial cell death pathways and in the
regulation of cellular bioenergetics3,4,80. Multiple studies revealed
that H2S donors help maintain mitochondrial integrity, reduce the
release of mitochondrial death signals, and attenuate
mitochondrially-regulated cell death responses of various
types79,81,82. Szabo et al.83 prepared a compound AP39 (Fig. 6)
with two moieties: ADT-OH for H2S generation and triphenyl-
phophinium (TPP) for mitochondrial targeting. Cell imaging
studies conﬁrmed that AP39 was primarily internalized in mito-
chondria84. After conﬁrming the mitochondria-targeting H2S
delivery, compound AP39 was employed to investigate its effect
on bioenergetics, viability, and mitochondrial DNA integrity in
bEnd.3 murine microvascular endothelial cells in vitro. At actures for HS NSAID hybrids.
ture for NBS112079 and AP39.
Hydrogen sulﬁde prodrugs 373concentration of 100 nmol/L, incubation of AP39 with bEnd.3
cells caused an increase in basal oxygen consumption rate (OCR),
which represented respiratory reserve capacity, a key bioenergetic
parameter. Meanwhile, AP39 (30 and 100 nmol/L) could also
induce an increase in FCCP (carbonyl cyanide 4-(triﬂuoromethoxy)
phenylhydrazone)-stimulated OCR. However, when the concentra-
tion of AP39 was increased to 300 nmol/L, an inhibitory effect was
observed instead. AP39 could also attenuate the loss of cellular
bioenergetics during oxidative stress caused by glucose oxidase.
Additionally, Co-treatment of ADT-OH with TPP targeting moiety
did not show any antioxidant or cytoprotective effect in oxidatively
stressed endothelial cells even at a concentration of 300 nM, which
is attributed to its inability to enter mitochondrial compartment. In
contrast, ADT-OH without the TPP targeting moiety did not show
any antioxidant or cytoprotective effect in oxidatively stressed
endothelial cells even at a concentration of 300 nmol/L, which is
attributed to its inability to enter mitochondrial compartment. In
summary, the various mitochondrial effects observed for AP39 are
consistent with the role of H2S in the regulation of mitochondrial
function.
Although DTT and its NSAID hybrids showed promising H2S-
related bioactivities both in vitro and in vivo, it is still unclear how
those agents release H2S in vivo. Hydrolysis for sure partially
contributes to the release of H2S from DTT. Because of the
presence of disulﬁde bonds in DTT, thiols could also activate DTT
through reduction to release H2S. Therefore, further experiments
are needed to elucidate its H2S release mechanism.
2.3. Controllable H2S prodrugs
The goal of controllable H2S prodrugs was to develop H2S
prodrugs, which are stable in aqueous solutions and during sample
preparation85. The prodrugs can release H2S in the presence of
triggers, which could be enzymes, pH, biomolecules, UV-light,
and others. However, this is still a great challenge in this ﬁeld.
Currently, there are three examples: thiol activation, light activa-
tion, and bicarbonate activation.
2.3.1. Thiol activation
In 2011 Xian's group85 developed the ﬁrst thiol activated H2S
prodrugs: N-mercapto (N-SH)-based derivatives. The strategy was
based on the instability of the N-SH bond. The thiol group was
ﬁrst protected with acyl groups, and then the protected nitrogen-
sulfur bond could be stable to some degree. In the presence of thiol
species in the biological system, H2S release can be triggered
through reduction. A detail mechanism is shown in Scheme 4. The
prodrug is ﬁrst activated by thiol exchange between a thiol species
(cysteine or GSH) and the prodrug to generate S-acylated cysteineScheme 4 Proposed N-SH H2S proand N-mercaptobenzamide. Then one of the intermediates, N-
mercaptobenzamide, reacts with cysteine to form cysteine perthiol,
which is followed by interaction with cysteine to release H2S. In
this mechanistic study, the Xian's group found that perthiol could
also be a key intermediate in H2S generation. In 2013, Xian's lab
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published a series of perthiol-based H2S prodrugs, with a release
mechanism similar to that of the previous example. Brieﬂy, thiol
exchange initiates the reaction to form penicillamine perthiol
intermediate, which is followed by thiol attack again to produce
either a disulﬁde and H2S (Scheme 5, pathway a,), or a new
perthiol, which would interact with another thiol species to release
H2S (Scheme 5, pathway b).
To show the therapeutic potential of perthiol H2S prodrugs,
Xian's laboratory also tested the protective effect of these
prodrugs against myocardial ischemia/reperfusion (MI/R) injury
in a murine model system, since H2S was proven to show such
effects. In these experiments, mice were subjected to 45 min left
ventricular ischemia followed by 24 h reperfusion. Then pro-
drugs or vehicles were administered into the left ventricular
lumen at 22.5 min of myocardial ischemia. Compared to
vehicle-treatment alone, mice treated with prodrugs displayed
a signiﬁcant reduction in circulating levels of cardiac troponin I
and myocardial infarct size per area-at-risk, suggesting that
perthiol H2S prodrugs indeed exhibit cardiac protection in MI/R
injury. It should be noted that the reaction between prodrugs
and cysteine yields many reactive sulfane sulfur species.
Therefore, further studies on H2S-related and sulfane sulfur-
related mechanisms are still needed.
Based on similar strategies, Calderone and coworkers87 reported
dithioperoxyanhydride as a thiol-activated H2S prodrugs in 2013.
The acylpersulﬁdes were proposed to be key intermediates. The
H2S-releasing mechanism is the same as that of perthiol H2S
prodrugs (Scheme 6).2.3.2. Photo-induced H2S prodrugs
The second type of controllable H2S prodrugs is light-activated
H2S prodrugs. Recently, there have been two example pub-
lished. The ﬁrst one is gem-dithiol-based-H2S prodrugs. In
2013, Xian and coworkers88 identiﬁed geminal-dithiol (gem-
dithiol) as a structure, which could release H2S in aqueous
solution. Then a photo-cleavable structure (a 2-nitrobenzyl
group) was introduced to protect the gem-thiols group. When
the molecules were exposed to UV-light, gem-dithiols were
regenerated. Subsequent hydrolysis leads to H2S release. Based
on this strategy, several gem-dithiol-based H2S prodrugs were
prepared. Methylene Blue assay indicated that 200 μmol/L
prodrugs could generate a peak concentration of 36 μmol/L
H2S under UV irradiation (365 nm). However, there are twodrugs H2S releasing mechanism.
Scheme 5 Proposed perthiol H2S prodrugs H2S releasing mechanism.
Scheme 6 Proposed dithioperoxyanhydride H2S releasing mechanism.
Scheme 7 H2S release from photo-induced H2S prodrugs.
Scheme 8 Proposed mechanism of H2S release from thiolamino
acids.
Scheme 9 Amidation of thiolacid.
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depends on the hydrolysis of gem-dithol, which is nearly ﬁxed.
Second, the reactive byproducts 2-nitrosobenzaldehyde can
react with H2S, which results in diminishing H2S generation.
Later, Nakagawa's group89 investigated another type of photo-
induced H2S prodrugs: ketoprofenate-caged H2S prodrugs
(Scheme 7). Upon UV irradiation (300–350 nm) for 10 min,
500 μmol/L of the prodrug would generate 30 μmol/L of H2S in
fetal bovine serum together with 2-propenylbenzophenone and
CO2. These two photo-induced H2S prodrugs successfully
demonstrated the photo-triggering concept, but the cytotoxicity
induced by UV-light could limit their applications.2.3.3. Thiolamino acid
Thiolamino acids as the third class of controllable H2S-releasing
prodrugs were ﬁrst reported by Giannis and coworkers90 in 2012.
Thioglycine and thiovaline were shown to release H2S in the
presence of bicarbonate under physiological conditions. The
mechanism is shown in Scheme 8.The thioamino acids interacted with bicarbonate to form
carbamate intermediates, which undergoes a cyclization reaction
leading to N-carboxyanhydride and H2S release (Scheme 8).
1H NMR spectroscopy studies were carried out to measure the
decomposition of thioglycine in the presence of NaHCO3. In a
40 mmol/L bicarbonate solution at 40 1C, 35% N-carboxyanhydride
were formed in 72 h. Since there is a high bicarbonate concentra-
tion (27 mmol/L) in blood at physiological pH, thiolamino
acids can be an H2S prodrug candidate. Giannis and
coworkers91 compared the H2S-releasing capacities of thiol-
amino acids with that of GYY4137. About 50 μmol/L H2S from
100 μmol/L of thioglycine could be detected by a ﬂuorescent
probe dibromobimane, while GYY4137 liberated less H2S at the
same condition. Giannis and coworkers also tested the pharmaco-
logical beneﬁts of such H2S prodrugs. Results showed that
thioglycine and thiovaline could enhance intracellular cyclic
guanosine monophosphate (cGMP) concentration and promote
vasorelaxation. One possible limit of the bicarbonate activated H2S
prodrugs stems from the reactivity of thiolamino acids, which
could quickly undergo amidation reaction under aerobic conditions
(Scheme 9)91.
Hydrogen sulﬁde prodrugs 3753. Conclusions
The review gives a brief summary of the current state of H2S
prodrugs. These prodrugs not only play an important role as
research tools but also are promising candidates for the develop-
ment of therapeutic agents. All prodrugs have their advantages,
and also limitations. The most challenging in this ﬁeld is still the
development of prodrugs with precise control of the release
kinetics so that they mimic endogenous H2S generation. The
effects of prodrugs themselves and the byproducts need to be taken
into consideration in all the biological experiments. Thus, new
hydrogen sulﬁde prodrugs with improved control of release
kinetics are needed in this ﬁeld.References
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